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Abstract. The control of serum phosphorus (P) and calcium-
phosphate (Ca  P) product is critical to the prevention of
ectopic calcification in chronic renal failure (CRF). Whereas
calcium (Ca) salts, the most commonly used phosphate bind-
ers, markedly increase serum Ca and positive Ca balance, the
new calcium- and aluminum-free phosphate binder, sevelamer
hydrochloride (RenaGel), reduces serum P without altering
serum Ca in hemodialysis patients. Using an experimental
model of CRF, these studies compare sevelamer and calcium
carbonate (CaCO3) in the control of serum P, secondary hy-
perparathyroidism (SH), and ectopic calcifications. 5/6 ne-
phrectomized rats underwent one of the following treatments
for 3 mo: uremic  high-P diet (U-HP); UHP  3% CaCO3
(U-HPC); UHP  3% sevelamer (U-HPS). Sevelamer
treatment controlled serum P independent of increases in serum
Ca, thus reducing serum Ca  P product and further deterio-
ration of renal function, as indicated by the highest creatinine
clearances. Sevelamer was as effective as CaCO3 in the control
of high-P–induced SH, as shown by similar serum PTH levels,
parathyroid (PT) gland weight, and markers of PT hyperplasia.
Also, both P binders elicited similar efficacy in reducing the
myocardial and hepatic calcifications induced by uremia. How-
ever, sevelamer caused a dramatic reduction of renal Ca dep-
osition (29.8 8.6 g/g wet tissue) compared with both U-HP
(175.5  45.7 g/g wet tissue, P  0.01) and the U-HPC
(58.9  13.7 g/g wet tissue, P  0.04). Histochemical
analyses using Von Kossa and Alizarin red S staining of kidney
sections confirmed these findings. The high number of foci of
calcification in the kidney of uremic controls (108  25) was
reduced to 33.0  11.3 by CaCO3 and decreased even further
with sevelamer (16.4  8.9, P  0.02 versus CaCO3). Impor-
tantly, the degree of tubulointerstitial fibrosis was also mark-
edly lower in U-HPS (5%) compared with either U-HPC
(30%) or U-HP (50%). It is concluded that in experimental
CRF in rats, despite a similar control of serum P and SH,
sevelamer is more effective than CaCO3 in preventing renal Ca
deposition and tubulointerstitial fibrosis, including better pres-
ervation of renal function. These findings cannot be extrapo-
lated to human disease, and further studies in patients are
necessary to determine the benefits of either P binder.
In end-stage renal disease, hyperphosphatemia and elevated
calcium-phosphate (Ca  P) product associate with ectopic
calcifications and increased risk of calciphylaxis, resulting in
higher prevalence of morbidity and mortality from cardiovas-
cular events (1–6). High serum phosphorus (P) levels worsen
uremia-induced secondary hyperparathyroidism by enhancing
parathyroid hyperplasia and parathyroid hormone (PTH) syn-
thesis and secretion (7–8). Elevated PTH levels cause ectopic
calcification not only by enhancing serum P and Ca  P
product through inducing high bone turnover, but also by
increasing both serum and intracellular calcium (Ca) (9–10).
The control of serum P in patients with chronic renal failure is
therefore important to the prevention of increases in Ca  P
product, secondary hyperparathyroidism, and ectopic calcifi-
cations (9).
Dietary P restriction, dialysis treatment, and administration of
phosphate-binders are the current therapies for hyperphos-
phatemia in chronic renal failure. The most commonly used
phosphate-binders contain aluminum salts, calcium carbonate
(CaCO3), or calcium acetate. Calcium salts increase serum Ca and
could worsen soft tissue calcifications, especially in patients on
vitamin D therapy. Administration of 1,25(OH)2D3, while sup-
pressing PTH synthesis, increases intestinal Ca absorption and
calcium-phosphate mobilization from bone (9–10).
The role of P in the progression of renal failure (11) and the
protective effects of P restriction on renal function (12) have
been known for more than 20 yr. Chronic renal failure causes
a reduction in nephron mass and in P excretion. Phosphate
retention not only induces secondary hyperparathyroidism but
also accelerates renal failure by promoting renal calcification
(13). Gimenez et al. (14) showed a correlation between renal
Ca deposition, hyperphosphatemia, and the progression of re-
nal failure in 246 renal biopsies. Patients with serum creatinine
levels above 1.5 mg/dl had higher serum Ca P product, renal
Ca content, and histologic Ca deposition (14).
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Ibels et al. (15) showed that dietary restriction of P prevents
the progression of renal failure in nephrectomized rats. In
contrast, high dietary P induced a rapid deterioration of renal
function (16). Phosphorus toxicity associates with renal calci-
um-phosphate precipitation and tubulointerstitial damage, re-
sulting in acceleration of nephrocalcinosis (17).
In 1980, Walser (18) described the association between
CaCO3 administration in uremic patients and increases in se-
rum creatinine concentration after 2 to 4 wk of treatment. At
the time, he concluded that “. . . an increase in the serum Ca 
P product may accelerate progression of renal failure and
suggest caution in the use of calcium supplements for this
reason.”
To reduce the side effects of the commonly used calcium
salts, a new aluminum- and calcium-free phosphate-binder was
developed. Poly-allylamine hydrochloride (sevelamer hydro-
chloride, RenaGel; GelTex Pharmaceuticals, Inc, Waltham,
MA) controls serum P levels with no hypercalcemia. Further-
more, sevelamer reduces LDL cholesterol by 30% and in-
creases HDL cholesterol by 18% (19).
The present studies compare sevelamer and CaCO3 in the
control of serum P, prevention of secondary hyperparathyroid-
ism, and reduction of renal calcifications in an experimental
model of chronic renal failure. Sevelamer and CaCO3 are
equally effective in reducing serum P levels and in preventing
secondary hyperparathyroidism. Importantly, sevelamer is
more effective than CaCO3 in preventing increases in serum Ca
 P product and in reducing renal Ca deposition, including
better preservation of renal function.
Materials and Methods
Experimental Protocol
Uremic (5/6-nephrectomized) female Sprague-Dawley rats aged 5
to 6 wk and weighing 200 to 225 g were studied. For 5/6-nephrec-
tomy, several branches of the left renal artery were ligated and the
right kidney excised. After 7 d of uremia, blood was taken to control
serum creatinine, Ca, and P, and rats were allocated to three groups
with similar renal function and serum Ca  P product. Uremic rats
then underwent one of the following dietary regimens for 12 wk: (a)
high-P diet (0.9% P; 0.6% Ca) (U-HP); (b) high-P diet  3% CaCO3
(U-HPC); and (c) high-P diet  3% sevelamer (U-HPS). Pow-
dered diets were purchased from Dyets, Inc. (Bethlehem, PA). Both
CaCO3 (Sigma Chemical, St. Louis, MO) and sevelamer hydrochlo-
ride (RenaGel) were added to the high-P diet daily.
All experimental protocols were approved by the Animal Study
Committee at Washington University School of Medicine.
Analytical Determinations
Rats were weighed monthly, and blood was drawn (tail vein) at 1,
4, and 8 wk to monitor serum creatinine, Ca, P, and Ca  P product.
On the last 5 d of treatment, rats were placed in metabolic cages.
Twenty four–hour urine were collected, and daily dietary intake was
monitored. Results were taken from the last 3 d of treatment. After 12
wk, rats were anesthetized and sacrificed by exsanguination. Arterial
blood (aortic puncture) was drawn for analytical determinations.
Urine samples were acidified, and each 24-h urine sample was ana-
lyzed for creatinine, calcium, and phosphorus. Plasma and urinary
phosphate, and serum and urinary creatinine were determined using an
autoanalyzer (COBAS-MIRA Plus, Branchburg, NJ). Total serum and
urinary calcium were measured by atomic absorption spectrophotom-
etry using a Perkin-Elmer 1100B spectrophotometer (Perkin-Elmer,
Norwalk, CT). Creatinine clearance measurements were calculated
using the standard formula: CCr  (UCr  Vu)/SCr. Urinary excretion
is expressed as milligrams of total calcium or phosphorus excreted in
24 h. Intact PTH levels were measured by an immunoradiometric
assay specific for intact rat PTH (Immunotopics, San Clemente, CA).
Parathyroid glands were surgically removed and weighed on a
CAHN-31 microbalance (Cahn Instruments, Inc. Cerritos, CA).
1,25(OH)2D3 levels were measured in plasma samples using the solid
phase extraction procedure and radioreceptor assay by Hollis et al.
(20).
Immunohistochemical Analyses of Parathyroid Glands
Immunohistochemical staining for proliferating cell nuclear anti-
gen (PCNA) and transforming growth factor- (TGF-) was per-
formed on sections of 10% neutral buffered formalin-fixed overnight
at 4°C and switched to 70% ethanol, paraffin embedded parathyroid
glands following protocols described in previous studies (21). Spec-
ificity of the primary antibodies was tested by immunohistochemical
staining of rat parathyroid tissue replacing the primary antibody with
mouse IgG1. For TGF- immunostaining, parathyroid tissue was
pretreated with 0.05% saponin for 30 min at room temperature. Tissue
was then blocked with 10% preimmune goat serum and incubated
with primary antibody (1.13 g/ml for PCNA; 10 g/ml for TGF-)
for 12 h at room temperature. Twenty-four consecutive sections of
tissue were cut for each parathyroid gland. Immunohistochemical
staining was evaluated independently by three different blinded indi-
viduals. Ten different tissue sections were analyzed per rat for each
experimental condition.
Immunohistochemical staining of PCNA protein was quantitated
using a Nikon Diaphot-TMD microscope coupled to a camera and an
image analysis system. Images of stained tissue sections were ac-
quired using a DAGE-330 color camera and captured with a Pentium
P-166 IBM compatible computer. The digitized images were con-
verted to a gray scale and analyzed using Image-Pro plus software
(Media Cybernetics) according to Mize’s study (22) as described
before (21). To eliminate variation, the microscope light source in-
tensity used during image capture was kept constant for all sections
stained on a given day.
Quantification of Calcium Deposition in Kidney,
Myocardium, and Liver
Calcium content in kidney, myocardium, and liver was measured as
described by Jono et al. (23). Tissue (three samples for each remnant
kidney, myocardium, or liver) was weighed on a CAHN-31 microbal-
ance (Cahn Instruments, Inc) and decalcified with 0.6 N HCl for 24 h.
The calcium content of HCl supernatants was determined by atomic
absorption spectrophotometry using a Perkin-Elmer 1100B spectro-
photometer. Calcium content in each sample was corrected by wet
tissue weight and expressed as g Ca/g wet tissue.
Morphologic Analysis of Kidney Calcification
After sacrifice, the remnant kidney was removed and cleaned of
fascia and adipose tissue. Sagittal sections of renal tissue were fixed
in buffered formalin. Five-micrometer sections were stained with
hematoxylin-eosin and with periodic acid-Schiff (PAS) and then
processed for light microscopic evaluation.
The entire tissue section was evaluated for calcium deposition by
von Kossa and Alizarin red S stains as follows. For von Kossa stain,
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slides were deparaffinized and hydrated to water. Five-percent silver
nitrate solution (S-01334, Sigma) was placed on the slides and incu-
bated for 1 h. Slides were rinsed four times in distilled water, placed
in thiosulfate solution for 5 min, and counterstained in nuclear fast red
solution for 5 min. Slides were then rinsed in tap water, dehydrated,
cleared in 95% ethylalcohol, 100% ethylalcohol, and xylene, and
cover slips were mounted. For Alizarin red S stain, slides were
deparaffinized, hydrated, and placed in Alizarin red S solution (Al-
izarin sodium monosulfonate from A-3757, Sigma). When red-orange
color appeared, excess stain was taken off. Slides were counterstained,
cleared, and mounted as previously reported (24). For Alizarin red S
stain, the tissue was viewed under polarized light. Semiquantitative
counts of calcifications were performed as follows. The entire kidney
section was examined, and all the foci of calcification were counted
(four kidney sections per animal, for a total of five rats per group).
Histologic features were quantified by three different individuals
blinded to treatment of the rats.
Statistical Analyses
ANOVA was employed to assess statistical differences between all
experimental groups tested. Multiple comparisons using the stringent
Bonferroni test measured the statistical significance of the differences
between every possible two-group comparison. Unpaired two-tailed t
test was used to compare baseline and uremia 3-mo time points within
experimental groups.
Results
The efficacy of sevelamer and CaCO3 in preventing high
P–induced secondary hyperparathyroidism and renal calcifica-
tions was determined 3 mo after induction of renal insuffi-
ciency by 5/6-nephrectomy, in rats.
Serum Chemistry
Table 1 shows serum chemistries in uremic rats for all the
experimental conditions tested at the beginning of the study
and after the 3 mo of treatment. Serum creatinine increased in
uremic control animals fed the high-P diet from a basal of 1.5
 0.1 to 2.3  0.2 mg/dl (P  0.01) after 3 mo of uremia. The
increase in serum creatinine levels was prevented in uremic
rats fed the same high-P diet by treatment with either sevel-
amer (1.4  0.2 mg/dl; P  0.05) or CaCO3 (1.7  0.2 mg/dl;
P  0.05).
Serum P levels decreased in both sevelamer (6.5  0.9
mg/dl; P  0.01) and CaCO3 (7.5  0.5 mg/dl; P  0.01)
groups compared with uremic controls (11.9  0.7 mg/dl). At
the doses tested, there were no significant differences in serum
P between sevelamer- and CaCO3-treated animals.
As expected, serum total Ca was higher in the uremic rats
treated with CaCO3 (10.6  0.1 mg/dl) compared with those
receiving sevelamer (9.5  0.1 mg/dl; P  0.05) or uremic
controls (8.6  0.5 mg/dl; P  0.01).
Serum Ca  P product was reduced in both sevelamer-
treated uremic rats (110  6.8 to 61  8.3 mg2/dl2; P  0.01)
and the CaCO3 group (109  3.8 to 80  5.3 mg2/dl2; P 
0.01). Importantly, only in the sevelamer-treated group, the
serum Ca  P product differed significantly from that in
Table 1. Serum chemistrya
U-HP
(n  7)
U-HPS
(n  7)
U-HPC
(n  7)
Creatinine (mg/dl)
baseline 1.5 0.1 1.6 0.1 1.7 0.1
uremia (3 mo) 2.3 0.2e 1.4 0.2c 1.7 0.2c
Phosphorus (mg/dl)
baseline 9.2 0.3 10.5 0.3 10.4 0.3
uremia (3 mo) 11.9 0.7e 6.5 0.9be 7.5 0.5be
Calcium (mg/dl)
baseline 10.1 0.1 10.5  0.3 10.5 0.3
uremia (3 mo) 8.6 0.5f 9.5 0.1f 10.6 0.1bd
Ca  P product (mg2/dl2)
baseline 92 3.8 110 6.8 109 3.8
uremia (3 mo) 101 4.5 61  8.3be 80 5.3e
pH
baseline 7.39 0.01 7.43 0.02 7.46 0.02
uremia (3 mo) 7.30 0.03e 7.37 0.01ce 7.39 0.01ce
a Uremic (5/6-nephrectomized) rats underwent one of the following experimental protocols for 3 mo: uremic control  high-phosphorus
diet (U-HP); uremic  HP diet  3% sevelamer (U-HPS); uremic  HP diet  3% calcium carbonate (U-HPC). Values represent the
mean  SEM; n  number of rats.
b P  0.01 versus U-HP from Bonferroni analysis.
c P  0.05 versus U-HP from Bonferroni analysis.
d P  0.05 versus U-HPS from Bonferroni analysis.
e P  0.01 comparing baseline and uremia (3 mo) time points, comparing unpaired two tailed t test.
f P  0.05 comparing baseline and uremia (3 mo) time points, comparing unpaired two tailed t test.
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uremic-untreated animals (61  8.3 mg2/dl2 versus 101  4.5
mg2/dl2; P  0.05).
Although serum pH decreased with the progression of renal
failure in all experimental groups, both sevelamer and CaCO3
prevented the drop in pH below the physiologic range that
occurred in uremic controls.
Serum 1,25(OH)2D3 levels did not differ significantly be-
tween uremic controls (20.2  3.8 pg/ml) and sevelamer-
treated animals (17.0  4.5 pg/ml) but were reduced in the
CaCO3 group (10.3  4.3 pg/ml).
Creatinine Clearance, Urinary Calcium, and
Urinary Phosphorus
As shown in Table 2, the reduction in creatinine clearance in
the U-HP (0.30  0.05 ml/min) group was prevented only by
sevelamer treatment (0.60  0.14 ml/min; P  0.01), whereas
CaCO3 had no effect (0.36  0.04 ml/min).
Treatment with CaCO3 increased 24-h urinary Ca excretion
from 8.9 0.8 mg/24 h in uremic controls to 18.6 3.1 mg/24
h (P  0.01), whereas sevelamer induced a modest increase to
13.2  1.9 mg/24 h (P  0.05), a value significantly lower
than that observed with CaCO3 treatment (P  0.05).
Table 2 shows that 24-h urinary phosphorus decreased from
201  13 mg/24 h in the uremic control group to 150  15
mg/24 h with sevelamer treatment and to 137  16 mg/24 h
with CaCO3. As with serum phosphorus levels, the decrease in
urinary phosphate was not different between sevelamer and
CaCO3-treated rats.
Effects of Sevelamer and CaCO3 on Serum PTH and
Parathyroid Gland Growth
Figure 1A depicts serum PTH levels in each experimental
condition. In the untreated uremic rats fed the high-P diet,
serum PTH (1808  150 pg/ml) levels were much higher than
in the CaCO3- or sevelamer-treated rats fed the same diet. Both
sevelamer (387  48 pg/ml; P  0.01) and CaCO3 (356  50
pg/ml; P 0.01) prevented the increase in serum PTH induced
by high dietary P.
Figure 1B shows the effects of the sevelamer and CaCO3
treatment on parathyroid gland weight. In untreated uremic rats
fed high-P diet, the weight of the parathyroid glands was
higher (3.99  0.44 g/g body wt) than in treated animals fed
the same diet. Both sevelamer (1.81 0.75 g/g body wt; P
0.01) and CaCO3 (1.52  0.42 g/g body wt; P  0.01)
prevented the enhancement of parathyroid gland growth ob-
served in uremic rats fed a high P diet.
Table 2. Creatinine clearance, urinary phosphorus, and urinary calciuma
U-HP
(n  7)
U-HPS
(n  7)
U-HPC
(n  7)
Creatinine clearance (ml/min) 0.30 0.05 0.60 0.14bc 0.36 0.04
Calcium (mg/24 h) 8.9 0.8 13.2  1.9de 18.6 3.1b
Phosphorus (mg/24 h) 201 13 150 15d 137 16b
a Uremic (5/6-nephrectomized) rats underwent one of the following experimental protocols for 3 mo: uremic control  high-phosphorus
diet (U-HP); uremic  HP diet  3% sevelamer (U-HPS); uremic  HP diet  3% calcium carbonate (U-HPC). Values represent the
mean  SEM from three different 24-h urine collections. n  number of rats.
b P  0.01 versus U-HP.
c P  0.01 versus U-HPC.
d P  0.05 versus U-HP.
e P  0.05 versus U-HPC from Bonferroni analysis.
Figure 1. Effects of sevelamer and CaCO3 on serum parathyroid
hormone (PTH) and parathyroid gland growth. Serum PTH (A) and
parathyroid gland weight (B) in uremic (5/6-nephrectomized) rats
undergoing one of the following experimental protocols for 3 mo:
uremic control  high-phosphorus diet (U-HP) (closed bars); uremic
 HP diet 3% sevelamer (U-HPS) (open bars); uremic HP diet
 3% calcium carbonate (U-HPC) (hatched bars). Results represent
the mean and SEM from seven rats per group. P values were obtained
by ANOVA and Bonferroni tests.
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To directly measure parathyroid cell proliferation rates, we
examined immunohistochemical expression of PCNA, a
marker of mitotic activity, and TGF-, a marker associated
with uremia- and high P–induced parathyroid hyperplasia. Fig-
ure 2 (upper panels) shows higher levels of PCNA and TGF-
in a parathyroid gland from uremic rats fed a high-P diet
compared with CaCO3- (middle panels) or sevelamer-treated
(lower panels) groups. Parathyroid PCNA expression after 3
mo of uremia was lower (40% reduction) in rats fed the high-P
diet when treated with either sevelamer or CaCO3.
These findings demonstrate that sevelamer is as effective as
CaCO3 in reducing both parathyroid hormone secretion and
parathyroid-cell growth induced by uremia and high dietary
phosphorus.
Figure 2. Effects of sevelamer and CaCO3 on parathyroid proliferating cell nuclear antigen (PCNA) and transforming growth factor- (TGF-)
expression. Representative photomicrographs of immunohistochemical staining of PCNA and TGF- expression in rat parathyroid tissue from
5/6-nephrectomized controls (top panels) or rats treated with either calcium carbonate (middle panels) or sevelamer (bottom panels).
Magnifications: 400 for PCNA staining; 100 for TGF- staining.
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Effects of Sevelamer and CaCO3 on Calcium
Deposition in Myocardium and Liver
Chronic renal failure increased Ca content in rat myocar-
dium and liver compared with animals with normal renal
function fed the same high-P diet (13.1  8.5 versus 3.5  1.1
g/g wet myocardial tissue; 6.1  2.8 versus 2.9  0.6 g/g
wet liver tissue). Both sevelamer and CaCO3 reduced Ca
deposition in myocardium and liver. The decrease in Ca con-
tent at 3 mo did not differ with either phosphate binder.
Effects of Sevelamer and CaCO3 on Renal
Calcium Deposition
Figure 3 shows kidney Ca content in all experimental
groups. Uremia markedly increased kidney Ca content com-
pared with rats with normal renal function fed the same high-P
diet (175.5 45.7 versus 5.8 0.8 g/g wet tissue; P 0.01).
Most importantly, a dramatic reduction of renal Ca deposition
was observed in the sevelamer group (29.8  8.6 g/g wet
tissue) compared with both uremic controls (175.5 45.7 g/g
wet tissue; P  0.01) and the CaCO3 group (58.9  13.7 g/g
wet tissue; P  0.04).
Effects of Sevelamer and CaCO3 on Calcification of
Kidney Tissue
Calcifications seen on kidney hematoxylin-eosin–stained
sections were highlighted with von Kossa and Alizarin red S
staining. Representative kidney sections from each experimen-
tal group depicting different staining are shown in Figure 4. An
apparent significant decrease in kidney calcifications in the
sevelamer-treated group is shown in Figure 4 (lower panels) in
comparison with uremic controls (upper panels) or rats treated
with CaCO3 (middle panels). In addition, the higher number of
foci of calcification found in uremic controls (108  25),
measured by semiquantitative analysis of kidney calcifications,
was reduced by CaCO3 (33.0  11.3) and even further by
sevelamer (16.4  8.9;p P  0.02 versus CaCO3) (Figure 5).
Furthermore, in uremic rats fed high-P diet, the remnant
kidney sections showed severe interstitial fibrosis and tubular
dilatation, occupying approximately 50% of the kidney surface
area. Significant acute and chronic inflammation were detected
as well. Periglomerular fibrosis and increased number of glo-
bally sclerosed glomeruli were present. In contrast, the remnant
kidneys in CaCO3-treated rats showed less interstitial inflam-
mation, fibrosis and tubular atrophy, occupying about 30% of
the kidney surface area. Most importantly, the renal histology
in sevelamer-treated rats was almost free of inflammation,
interstitial fibrosis, and tubular dilatation (5% of the kidney
surface area). Figure 6 depicts the described histologic findings
in the corresponding animals.
Discussion
These studies demonstrate in rats with chronic renal failure
that, despite the similar efficacy of sevelamer hydrochloride
and CaCO3 in controlling serum phosphorus and secondary
hyperparathyroidism, sevelamer better prevents renal calcium
deposition, preserving renal function.
Hyperphosphatemia due to decreased P excretion (25,26)
worsens secondary hyperparathyroidism, which is commonly
present in patients with chronic renal failure. High serum P
directly enhances parathyroid cell proliferation and PTH syn-
thesis and secretion (6,7). High P also enhances parathyroid
function indirectly by decreasing calcitriol synthesis and serum
ionized Ca levels, which further elevates circulating PTH
(27,28). High serum PTH induces osteitis fibrosa and bone
loss, thus increasing serum Ca P product (29,30) and ectopic
calcification (3,31). In addition to the described effects regard-
ing bone resorption, high PTH may also cause metastatic
microcalcifications through elevations in cytosolic Ca (9,10).
In rats, Borle et al. (16) showed that high P-induced hyper-
parathyroidism caused nephrocalcinosis. Elevated levels of
serum PTH induced intracellular Ca accumulation and Ca-P
deposition in renal tissue (16).
Conversely, P restriction counteracts the mitogenic signals
for parathyroid hyperplasia triggered by renal failure, thus
preventing parathyroid gland enlargement (7). Furthermore, in
an experimental model of established secondary hyperparathy-
roidism, the switch from high P intake to P restriction normal-
ized serum PTH levels within 1 wk (32). The molecular mech-
anisms by which phosphate restrictions effectively suppress
hyperparathyroidism are incompletely understood. However, it
is clear that the control of serum P is critical for effective
treatment in renal failure patients. Because of difficulties with
patients’ compliance to a P restricted diet, the current treatment
of hyperphosphatemia demands phosphate binders. One obvi-
ous limitation of calcium-based phosphate binders, increased
Ca load and serum Ca in patients with end-stage renal disease
Figure 3. Effects of sevelamer and CaCO3 on renal calcium content.
Renal calcium deposition in normal and uremic (5/6-nephrectomized)
rats undergoing one of the following experimental protocols for 3 mo:
normal  high-phosphorus diet (N-HP) (gray bar); uremic control 
HP diet (U-HP) (closed bar); uremic  HP diet  3% sevelamer
(U-HPS) (open bar); uremic  HP diet  3% calcium carbonate
(U-HPC) (dashed bar). Bars and errors bars represent the mean and
SEM from seven rats. P values were obtained by ANOVA and
Bonferroni tests.
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(33–35), led to the development of a new phosphate binder,
sevelamer. In dialysis patients, this calcium- and aluminum-
free compound reduces serum phosphorus and PTH levels with
no hypercalcemia (19,36,37).
In the present studies of chronic renal failure in rats, sevel-
amer treatment reduced serum P independently of increases in
serum Ca levels, leading to a lower serum Ca  P product
when compared with uremic controls. Sevelamer reduction of
serum P appears to mediate its efficacy to control both para-
thyroid hyperplasia and PTH secretion; serum 1,25(OH)2D3
levels were similar between uremic controls and the sevelamer-
treated rats.
Although sevelamer and CaCO3 were equally effective in
controlling serum P levels and secondary hyperparathyroidism,
no difference in Ca  P product was evident between CaCO3-
treated rats and uremic controls. It is clear that an additional
factor, such as sevelamer’s improved control of the Ca  P
product, mediated the higher efficacy of sevelamer in reducing
renal Ca deposition. In fact, Ahmed et al. (38) showed an
association between hyperphosphatemia, elevated serum Ca 
P product, and calciphylaxis in dialysis patients. Although
nephrocalcinosis is not a common factor in the progression of
renal failure, Gimenez et al. (17) reported a significant positive
correlation between renal Ca content and serum creatinine in
patients with impaired renal failure. Biopsied patients with
serum creatinine higher than 1.5 mg/dl had higher levels of
serum P, serum Ca  P product, and renal Ca content (17).
Recent studies by Goodman (2) and Guerin (34) have impli-
cated the dose of calcium-based P binders as a risk for coronary
artery calcification in end-stage renal failure patients.
In our uremic rat model, there was no evidence of high
P–induced aortic calcifications 3 mo after the onset of renal
failure. However, Ca content in rat myocardium and liver was
higher than in normal controls. Both sevelamer and CaCO3
Figure 4. Effects of sevelamer and CaCO3 on kidney calcification. Representative photomicrographs of hematoxylin-eosin, von Kossa, and
Alizarin red S staining in remnant kidney tissue of 5/6-nephrectomized rats undergoing one of the following experimental protocols for 3 mo:
uremic control high-phosphorus diet (U-HP) (upper panels); uremic HP diet 3% calcium carbonate (U-HPC) (middle panels); uremic
 HP diet  3% sevelamer (U-HPS) (lower panels). Alizarin red S staining was used polarized microscopy.
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were equally effective in reducing Ca deposition in these
tissues.
Importantly, despite the similarities of sevelamer and
CaCO3 in controlling myocardial Ca deposition in rats after 3
mo of uremia and high-Pe diet, differences were evident when
Ca deposition was measured in the kidneys. These findings
suggest a tissue-specific and time-dependent sensitivity for Ca
 P product induction of calcification (Figure 4). In fact, there
was a significant reduction of renal Ca content in sevelamer-
treated rats compared with the CaCO3 group, also evident in
histologic studies using von Kossa and Alizarin red S staining
of kidney sections. Further validation came from the demon-
stration that sevelamer was more effective than CaCO3 in
preventing elevations in the number of foci of calcification
compared with uremic controls (Figure 5). These findings
suggest that the significant reduction of renal Ca deposition
found in the uremic rats treated with sevelamer may be in
association with the lower serum Ca  P product compared
with uremic controls and CaCO3-treated animals. Moreover,
renal function deterioration, assessed by measurements of cre-
atinine clearance, was prevented only in sevelamer-treated rats.
No differences in creatinine clearance were observed between
the uremic and the CaCO3-treated animals. In fact, the severe
tubulointerstitial fibrosis, present in remnant kidneys of uremic
rats fed high dietary P (50% of the kidney surface area), was
reduced to 30% of the kidney surface area by treatment with
CaCO3 and almost abolished in sevelamer-treated rats (5% of
the kidney surface area) (Figure 6). These data support the
existing evidence on the role of hyperphosphatemia in the
deterioration of renal failure in rats and the efficacy of sevel-
amer in better ameliorating its progression compared with
CaCO3.
In 5/6-nephrectomized rats, low dietary P prevented in-
creases in serum creatinine levels, improved kidney histology,
and decreased renal Ca content (14). Moreover, in uremic rats
fed a normal-P diet (0.5% P), renal histology presented exten-
sive tubulointerstitial lesions and nephrocalcinosis compared
with a low-P diet (0.2% P) (39). Furthermore, 5/6-nephrecto-
mized rats placed on high-P (1.0% or 2.0%) diets developed
higher renal Ca content and more histologic damage compared
with animals on a normal-P (0.5%) diet (11). The demonstra-
tion in our experimental model in the rat that both P binders
were equally effective in controlling serum P indicates that the
lower Ca  P product in the sevelamer group may be the main
determinant of its advantage in a better preservation of renal
function.
In conclusion, sevelamer is an effective agent in reducing Ca
 P product, preventing kidney calcification, and preserving
renal function in uremic rats. These findings cannot be extrap-
olated to human disease, and further studies in patients are
Figure 6. Effects of sevelamer and CaCO3 on kidney histology. Representative photomicrographs of periodic acid-Schiff (PAS) staining in
remnant kidney tissue of 5/6-nephrectomized rats undergoing one of the following experimental protocols for 3 mo: Uremic control 
high-phosphorus diet (U-HP) (right panel); uremic  HP diet  3% calcium carbonate (U-HPC) (middle panel); and uremic  HP diet 
3% sevelamer (U-HPS) (left panel). Magnification, 400.
Figure 5. Effects of sevelamer and CaCO3 on kidney foci of calcifi-
cation. Mean of foci of calcification in remnant kidney tissue uremic
(5/6-nephrectomized) rats undergoing one of the following experi-
mental protocols for 3 mo: uremic control  high-phosphorus diet
(U-HP) (closed bar); uremic  HP diet  3% sevelamer (U-HPS)
(open bar); uremic  HP diet  3% calcium carbonate (U-HPC)
(dashed bar). Results represent the mean and SEM from four sections/
rat in five rats per group. P values were obtained by ANOVA and
Bonferroni tests. Magnification, 20.
2306 Journal of the American Society of Nephrology J Am Soc Nephrol 13: 2299–2308, 2002
necessary to determine the benefits of either (CaCO3 versus
sevelamer) P binder.
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